30 results about "Fibroma" patented technology

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

The invention belongs to the technical field of traditional Chinese medicine, and discloses a preparation method and application of yang-strengthening navel treatment cream, and the key point of the technical scheme is that the yang-strengthening navel treatment cream is prepared from the following medicinal materials in parts by weight: 25-35g of prepared rehmannia root, 25-35g of deer-horn glue, 2-8g of cinnamon, 2-8g of ephedra, 15g of garden balsam stem, 3-9g of notopterygium root, 10-20g of semen brassicae, 5-15g of corydalis tuber, 2-8g of ginger charcoal, 5-15g of geranium wilfordii and 5-15g of liquorice. The traditional Chinese medicine composition has the effects of warming yang and enriching blood, and dispelling cold and removing stagnation, and is suitable for symptoms such as neck, shoulder, waist and leg pain, sciatica, chronic bronchitis, asthma, dysmenorrhea, thyroid nodule, pulmonary nodule, hyperplasia of mammary glands, mammary cyst, mammary fibroma, hysteromyoma and the like caused by yang deficiency and cold coagulation.

Compositions, methods, and uses for injecting hydrogels of ablative chemicals are described. The hydrogel is biodegradable and can be formed in situ. The hydrogel is effective to deliver tissue ablative chemicals to a target site. The tissue ablative chemicals delivered by the hydrogel may also be particularly effective for intrauterine ablation (even in the presence of fibroma) or for scar treatment of fallopian tubes by minimally invasive surgery for birth control. The hydrogel may also particularly effectively avoid tissue ablative chemicals from contacting non-target tissue. The hydrogels may be implanted using a variety of delivery carriers, including injections and catheters. The hydrogel may be designed to be limited to a target site for a time of several hours to several days such that target tissue ablation may be performed within a walkable patient. Methods are described for the transcervical placement of an in situ formed hydrogel into the uterus or one or more fallopian tubes.

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

Provided herein are compositions used to reduce fibrotic tissues associated with an integumentary system fibromatosis condition. Methods of using the compositions to reduce fibrotic tissues associated with an integumentary system fibromatosis condition are also disclosed.

In one embodiment, the present application discloses, in part, biologically active compositions comprising a Crila® composition, or an admixture of Crinum latifolium L. dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the Crinum latifolium L. dry extract to EGCG, and their use in the treatment of intramural or subserosal fibroids and various related diseases.

The invention provides a culture method of a neurofibroma organ. The balling culture medium of the neurofibroma organ comprises EGF (epidermal growth factor) and FGF (fibroblast growth factor) with the concentration of 200-250ng The organoid culture method comprises the following steps: digesting neurofibroma tissue blocks to prepare a single-cell suspension; the single-cell suspension is placed in a culture dish treated by polylysine, a Schwann cell culture medium is added to be cultured for 24 hours, the Schwann cell culture medium contains forsklin and beta-heragulin needed by Schwann cell enrichment, and Schwann cell enrichment liquid is obtained; collecting Schwann cell enrichment liquid, adding the balling culture medium and Y-27632, culturing for 6-12 hours, collecting cells, adding the balling culture medium, and culturing for 7-14 days. The tumor ball culture method comprises the following steps: culturing the organoid according to the method, digesting the organoid and culturing. According to the present invention, the Schwann cell screening step is added, the components of the balling culture medium are improved, and the Y-27632 is added, such that the problems of small tumor ball number and small size are solved, and the stable neurofibroma organ can be formed.

The application discloses application of FTY720 as a PP2A phosphatase activator in preparation of a medicine for treating type I neurofibromatosis. The application first uses FTY720 for treatment of type I neurofibromatosis, and proves that FTY720 significantly inhibits formation of neurofibromas by non-specifically activating PP2A phosphatase. In-vivo experimental results show that FTY720 as a single drug can significantly inhibit tumor growth, and a synergistic effect is presented when FTY720 is combined with a MEK inhibitor, and tumor growth is almost completely inhibited. In-vitro cell experiments show that FTY720 as a single drug or in combination with MEKi treatment can inhibit tumor Schwann cells from forming tumor spheres, inhibit cell proliferation and migration, and induce tumor cell apoptosis. The application overcomes the drug resistance problem existing in the prior art MEK inhibitor, and provides a new treatment strategy for type I neurofibromatosis. FTY720 is an FDA-approved drug, and has good safety and drugability, and has high clinical conversion potential.

The invention discloses siRNA (small interfering Ribonucleic Acid) for inhibiting the expression of a CREPT gene. The nucleotide sequence of a positive-sense strand of the siRNA is shown as any one of SEQ ID No. 1 to SEQ ID No. 3. The siRNA can be used for inhibiting CREPT (Cathode Reactive Part of siRNA can inhibit the growth of mouse colon cancer cells and the growth of NIH3T3 fibroblast cells. And the drug can be delivered through the liposome of the delivery system si-CREPT, so that the mouse liver cancer can be treated, and the tumor load of the mouse liver cancer can be remarkably reduced.

The invention relates to collagen 1 translation inhibitors and methods of use thereof. The present invention relates to novel collagen 1 translation inhibitors, compositions and processes for their preparation and their use for the treatment of fibrosis, including pulmonary fibrosis, hepatic fibrosis, renal fibrosis, cardiac fibrosis and skin fibrosis; an IPF; wound healing; scar formation and gingival fibromatosis; systemic sclerosis; alcoholic steatohepatitis; and non-alcoholic steatohepatitis (NASH).

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects. Where the methods of treatment include intralesionally injecting a pharmaceutical formulation comprising collagenase into one or more plantar fibromatosis nodules in one or both of the subject's feet or the population of subjects' feet to thereby treat the plantar fibromatosis. The collagenase has enzymatic activity in regards to collagen. The treatment may result in a change from a baseline or control of a scale to determine effectiveness.

Provided herein are compositions used to reduce fibrotic tissues associated with an integumentary system fibromatosis condition. Methods of using the compositions to reduce fibrotic tissues associated with an integumentary system fibromatosis condition are also disclosed.

This application relates, in certain embodiments, to a method and composition for treating soft tissue sarcomas (STS, e.g., spindle cell sarcoma, solitary fibrous tumor, or leiomyosarcoma) using a composition comprising nanoparticles containing an mTOR inhibitor (e.g., limus drugs, e.g., sirolimus or its derivatives) and albumin in combination with a multityrosine kinase inhibitor (e.g., pazopanib).

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

In one embodiment, the present application discloses, in part, biologically active compositions comprising a Crila® composition, or an admixture of Crinum latifolium L. dry extract (Crila®) and epigallocatechin gallate (EGCG), wherein the ratio of the Crinum latifolium L. dry extract to EGCG, and their use in the treatment of intramural or subserosal fibroids and various related diseases.

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

Provided are novel collagen 1 translational inhibitors, compositions comprising the same, methods of making the same, and uses thereof for treating fibrosis (including pulmonary fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, skin fibrosis), IPF (idiopathic pulmonary fibrosis), wound-healing, scar fibromatosis, gingival fibromatosis, systemic sclerosis, alcoholic fat hepatitis, and non-alcoholic fat hepatitis (NASH).SOLUTION: A compound of Formula V, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, isotopic variant, reverse amide analog, or any combination thereof is provided. Wherein X1, X2, X4, and X5 are each independently C or N; X3 is N.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biological medicine, and particularly relates to a kit for detecting a breast cancer methylation marker and application of the kit. The kit provided by the invention has a better detection effect on four types of breast cancer by detecting the methylation level of a combination of the ENPP2 gene and the NPTX2 gene in a sample, and the detection sensitivities of the kit to breast cancer types with higher malignancy and poor prognosis of three-negative and HER-2 positive tumors can reach 94.29% and 93.75% respectively; the kit has relatively high detection specificity for mammary gland fibroma patients, mammary gland hyperplasia patients, mammary cyst patients and healthy people, detection of false negative and false positive results can be effectively avoided, and the detection accuracy is high.

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

The present invention relates to the use of vitamin D and an agent selected from epigallocatechin gallate (EGCG), catechins, epigallocatechin gallate and epicatechin gallate (ECG) for preventing, controlling and / or treating fibroids in a subject.

Disclosed are compositions, methods, uses, kits and articles of manufacture, which are based on the use of a hyaluronidase and a collagen-reducing agent, for reducing or inhibiting the development of fibrosis in a tissue, or for treating collagen-mediated disorders. In specific embodiments, the collagen-mediated disorders are fibroproliferative disorders involving alterations of collagen, including fibromatoses such as Dupuytren's disease. Peyronie's disease and Ledderhose's disease.

Systems and methods for treating a fibrous mass associated with a condition such as Morton's neuroma, plantar fibroma, or Achilles tendinopathy are disclosed. According to illustrative implementations, exemplary methods may comprise identifying a location of the fibrous mass and non-surgically delivering electromagnetic energy to the fibrous mass.

The invention discloses an application of deoxyelephantopin in an antitumor drug. In particular to application of deoxyelephantopin or pharmaceutically acceptable salt thereof in preparation of drugs for resisting nervous system tumors, and the nervous system tumors comprise at least one of glioma, meningioma, medulloblastoma, tumor in a pineal body region, pituitary adenoma, neurofibroma, neurosheath tumor and parangganglioma. The glioma comprises at least one of astrocytoma, oligodendroglia and ventricular canal membrane tumor. The application of deoxyelephantopin can inhibit proliferation and invasion of glioma cells through a multi-target path and induce glioma cell apoptosis. In animal model experiments, it is found that deoxyelephantopin can inhibit growth of glioma in nude mice, has little toxic and side effects on the liver and kidney of nude mice, and has a good application prospect.

The present invention relates to novel collagen 1 translation inhibitors, compositions and preparation methods thereof, and uses thereof for treating: fibrosis, including pulmonary fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis and skin fibrosis; IPF; wound healing; scar formation and gingival fibromatosis; systemic sclerosis; alcoholic steatohepatitis; and non-alcoholic steatohepatitis (NASH).

The application discloses siRNA for inhibiting expression of a CREPT gene, wherein a positive sense chain nucleotide sequence of the siRNA is shown in any one of SEQ ID No. 1-3. The siRNA can inhibit the CREPT. Some siRNAs can inhibit growth of mouse colon cancer cells and growth of NIH3T3 fibrosarcoma cells. The liposome delivery drug of the si-CREPT through a delivery system can treat mouse liver cancer, and significantly reduce tumor load of the mouse liver cancer.

The present disclosure relates to tissue controlled treatment and dynamic interaction and comparison with tissue and / or treatment data. An interactive treatment mapping and planning system enables a user to more quickly, thoroughly, and efficiently aggregate fibroid and / or treatment information from a user and / or one or more sets of databases, construct a fibroid map providing a visual representation of the aggregated fibroid information, generate information about a fibroid and / or treatment procedure to be treated from the aggregated information, develop a treatment plan based on the fibroid and / or treatment procedure information, provide real-time information collected from treatment devices during a treatment procedure, and allow a user to interact with treatment data.

The invention belongs to the field of drug delivery, and relates to a liposome preparation, in particular to pegylated liposome adriamycin and application thereof in treating advanced and refractory invasive fibroma. The pegylated liposome doxorubicin comprises doxorubicin hydrochloride, polyethylene glycol-lipid, cholesterol and phospholipid. The pegylated liposome doxorubicin liposome disclosed by the invention is small in particle size, high in encapsulation efficiency and high in stability, and has a remarkable curative effect on advanced and refractory invasive fibroma.

The present invention relates to an SOS1 inhibitor with a pyrido-fused-six-membered ring structure, a preparation method therefor, and use thereof. The SOS1 inhibitor has the structural formula shown in formula (I) and an inhibitory activity on SOS1, and can be used to treat head and neck cancer, lung cancer, a mediastinal tumor, a gastrointestinal tumor, prostate cancer, testicular cancer, a gynecological tumor, breast cancer, renal and bladder cancer, an endocrine tumor, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, mesothelioma, skin cancer, a peripheral nerve tumor, a central nervous system tumor, lymphoma, leukemia, Noonan syndrome, cardio-facio-cutaneous syndrome, and hereditary gingival fibromatosis and a related syndrome thereof.